- Stocks
- Healthcare
- NASDAQ: AMGN

Price (delayed)

$253.65

Market cap

$135.34B

P/E Ratio

20.26

Dividend/share

$7.76

EPS

$12.52

Enterprise value

$164.54B

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.

AMGN's EPS is up by 28% year-on-year and by 6% since the previous quarter

The net income has grown by 22% YoY and by 3.9% from the previous quarter

Amgen's equity has plunged by 56% YoY but it has soared by 51% from the previous quarter

The debt rose by 6% since the previous quarter and by 3% year-on-year

What are the main financial stats of AMGN

Market
Valuations
Earnings

Shares outstanding

533.58M

Market cap

$135.34B

Enterprise value

$164.54B

Price to earnings (P/E)

20.26

Price to book (P/B)

37.14

Price to sales (P/S)

5.15

EV/EBIT

18.17

EV/EBITDA

13.26

EV/Sales

6.25

Revenue

$26.33B

EBIT

$9.06B

EBITDA

$12.41B

Free cash flow

$9B

Per share
Balance sheet
Liquidity

EPS

$12.52

Free cash flow per share

$16.82

Book value per share

$6.83

Revenue per share

$49.21

TBVPS

$66.52

Total assets

$63.7B

Total liabilities

$60.05B

Debt

$38.7B

Equity

$3.65B

Working capital

$9.73B

Debt to equity

10.6

Current ratio

1.68

Quick ratio

1.17

Net debt/EBITDA

2.35

Margins
Efficiency
Dividend

EBITDA margin

47.1%

Gross margin

75.8%

Net margin

26%

Operating margin

36.6%

Return on assets

11.2%

Return on equity

199.7%

Return on invested capital

19%

Return on capital employed

18.3%

Return on sales

34.4%

Dividend yield

3.06%

DPS

$7.76

Payout ratio

62%

How has the Amgen stock price performed over time

Intraday

-0.48%

1 week

-3.64%

1 month

-3.7%

1 year

13.24%

YTD

-3.42%

QTD

-3.42%

How have Amgen's revenue and profit performed over time

Revenue

$26.33B

Gross profit

$19.95B

Operating income

$9.64B

Net income

$6.84B

Gross margin

75.8%

Net margin

26%

AMGN's operating income is up by 31% year-on-year and by 3% since the previous quarter

The company's operating margin rose by 28% YoY and by 3.1% QoQ

The net income has grown by 22% YoY and by 3.9% from the previous quarter

The net margin rose by 19% year-on-year and by 4.4% since the previous quarter

What is Amgen's growth rate over time

What is Amgen stock price valuation

P/E

20.26

P/B

37.14

P/S

5.15

EV/EBIT

18.17

EV/EBITDA

13.26

EV/Sales

6.25

AMGN's EPS is up by 28% year-on-year and by 6% since the previous quarter

The P/E is 16% below the 5-year quarterly average of 24.2 and 3.5% below the last 4 quarters average of 21.0

The stock's price to book (P/B) is 62% more than its 5-year quarterly average of 22.9 but 41% less than its last 4 quarters average of 63.2

Amgen's equity has plunged by 56% YoY but it has soared by 51% from the previous quarter

The P/S is 5% more than the last 4 quarters average of 4.9 but 2.8% less than the 5-year quarterly average of 5.3

The revenue has grown by 2.2% year-on-year

How efficient is Amgen business performance

The ROE has grown by 39% from the previous quarter

AMGN's return on assets is up by 24% year-on-year and by 3.7% since the previous quarter

AMGN's return on sales is up by 16% year-on-year and by 3.9% since the previous quarter

The ROIC has grown by 12% YoY

What is AMGN's dividend history

DPS

$7.76

Dividend yield

3.06%

Payout ratio

62%

Recent dividends

How did Amgen financials performed over time

Amgen's total assets is 6% more than its total liabilities

AMGN's quick ratio is up by 18% since the previous quarter

Amgen's current ratio has increased by 10% from the previous quarter and by 2.4% YoY

AMGN's debt to equity has soared by 132% YoY but it is down by 30% QoQ

Amgen's equity has plunged by 56% YoY but it has soared by 51% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.